FindTrial
Sign In

Research on the Expression of Mesothelin and Its Clinicopathological Significance in Patients with Triple Negative Breast Cancer

Research on the Expression of Mesothelin and Its Clinicopathological Significance in Patients with Triple Negative Breast Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100047923
Enrollment
Unknown
Registered
2021-06-27
Start date
2021-08-01
Completion date
Unknown
Last updated
2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

case series:none

Sponsors

The First Affiliated Hospital of Army Medical University, PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 80 Years

Inclusion criteria

Inclusion criteria: Two or more pathologists jointly read the films and confirmed the diagnosis of TNBC.

Exclusion criteria

Exclusion criteria: 1. Cases with undetermined tumor grade. 2. The researchers believe that other reasons are not suitable for clinical trials.

Design outcomes

Primary

MeasureTime frame
Mesothelin;—

Countries

China

Contacts

Public ContactYu Shicang
yushicang@163.com+86 13228685391

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026